Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q3 FY22 results · Oct–Dec 2021
Natco Pharma reported revenue from operations of ₹560.50 crore (up 57.8% from Q3 FY21) and net profit of ₹80.40 crore (up 26.8% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 560.50 | 355.20 | +57.8% | 377.20 | +48.6% |
| Other income | 30.20 | 30.80 | −1.9% | 38.00 | −20.5% |
| Total income | 590.70 | 386.00 | +53.0% | 415.20 | +42.3% |
| Profit before tax | 91.00 | 80.10 | +13.6% | 69.80 | +30.4% |
| Net profit for the period | 80.40 | 63.40 | +26.8% | 65.10 | +23.5% |
| EPS, basic (₹) | 4.41 | 3.44 | +28.2% | 3.57 | +23.5% |
| Net margin (%) | 14.3 | 17.8 | 17.3 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 529.50 | 330.90 | +60.0% | 330.40 | +60.3% |
| Other income | 31.60 | 24.90 | +26.9% | 40.30 | −21.6% |
| Total income | 561.10 | 355.80 | +57.7% | 370.70 | +51.4% |
| Profit before tax | 79.70 | 70.70 | +12.7% | 52.30 | +52.4% |
| Net profit for the period | 71.60 | 54.70 | +30.9% | 53.60 | +33.6% |
| EPS, basic (₹) | 3.93 | 3.00 | +31.0% | 2.94 | +33.7% |
| Net margin (%) | 13.5 | 16.5 | 16.2 |
Consolidated
- Filed with BSE
- 14 Feb 2022, 18:41 IST
- Board meeting
- 14 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Feb 2022, 18:41 IST
- Board meeting
- 14 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE